冠状动脉装置对抗性高血压的有效性:一个系统性审查
Ilayda Kayir1, Tanaisha Italia2, Avi A Gajjar3
1School of Medicine, Bahcesehir University, Istanbul, Turkey.
Journal of neurointerventional surgery
|January 6, 2026
概括
Carotid baroreceptor 装置在治疗抗性高血压 (RHT) 方面表现有前途. 巴罗斯蒂姆Neo为Rheos提供了一个更安全的替代品,而MobiusHD则需要对这种具有挑战性的条件进行进一步的安全评估.
科学领域:
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 神经学 神经学
背景情况:
- 抗性高血压 (RHT) 影响10-30%的高血压患者,增加心血管风险.
- 基于巴罗受体的疗法通过向自主神经系统,为RHT管理提供了一种新的方法.
研究的目的:
- 评估带气质受体装置 (Rheos,Barostim Neo,MobiusHD) 对于RHT的疗效和安全性.
- 评估它们降低血压 (BP) 的潜力.
主要方法:
- 在主要数据库 (PubMed/Medline,Scopus,Cochrane) 进行PRISMA指导的文献搜索,截至2024年8月.
- 对RHT患者原始疗效和安全性数据的研究进行选.
- 分析提取的关于研究设计,患者特征和结果的数据.
主要成果:
- 分析了16项研究:Rheos (8),Barostim Neo (5),MobiusHD (3). 这三项研究的结果是:
- 莱奥斯显示血压降低,但并发症;巴罗斯蒂姆Neo显示了与较少并发症相比较有效的效果.
- 莫比乌斯HD在3年内显著降低了血压,但携带了TIAs等程序风险.
结论:
- Carotid 装置是一个有前途的 RHT 治疗方法,Barostim Neo 似乎比 Rheos 更安全.
- 莫比乌斯HD显示有效性,但需要进一步的安全试验.
- 标准化试验和长期随访对于理解高血压中基于动脉的治疗方法至关重要.
关键词:
血压 血压 血压 血压相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Atherosclerosis III: Management
312
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
312
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
Heart Failure Drugs: β-Blockers
758
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758
Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209


